{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Respiratory+Syncytial+Virus+Prevention",
    "query": {
      "condition": "Respiratory Syncytial Virus Prevention"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 19,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Respiratory+Syncytial+Virus+Prevention&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-24T11:46:42.729Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03979313",
      "title": "A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Infections"
      ],
      "interventions": [
        {
          "name": "MEDI8897",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "1 Year",
        "sex": "ALL",
        "summary": "0 Years to 1 Year"
      },
      "enrollment_count": 3012,
      "start_date": "2019-07-23",
      "completion_date": "2023-03-21",
      "has_results": true,
      "last_update_posted_date": "2024-02-28",
      "last_synced_at": "2026-07-24T11:46:42.729Z",
      "location_count": 66,
      "location_summary": "Birmingham, Alabama • Fort Defiance, Arizona • Fayetteville, Arkansas + 59 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fort Defiance",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Downey",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03979313"
    },
    {
      "nct_id": "NCT00129766",
      "title": "Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Infections"
      ],
      "interventions": [
        {
          "name": "motavizumab (MEDI-524)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "palivizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "MedImmune LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "24 Months",
        "sex": "ALL",
        "summary": "Up to 24 Months"
      },
      "enrollment_count": 6635,
      "start_date": "2004-11",
      "completion_date": "2006-05",
      "has_results": true,
      "last_update_posted_date": "2013-08-28",
      "last_synced_at": "2026-07-24T11:46:42.729Z",
      "location_count": 120,
      "location_summary": "Birmingham, Alabama • Pike Road, Alabama • Phoenix, Arizona + 98 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Pike Road",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Benton",
          "state": "Arkansas"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00129766"
    },
    {
      "nct_id": "NCT03959488",
      "title": "A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Infections"
      ],
      "interventions": [
        {
          "name": "MEDI8897",
          "type": "DRUG"
        },
        {
          "name": "Palivizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "1 Year",
        "sex": "ALL",
        "summary": "0 Years to 1 Year"
      },
      "enrollment_count": 925,
      "start_date": "2019-07-30",
      "completion_date": "2023-01-20",
      "has_results": true,
      "last_update_posted_date": "2023-09-21",
      "last_synced_at": "2026-07-24T11:46:42.729Z",
      "location_count": 30,
      "location_summary": "Anaheim, California • Long Beach, California • Los Angeles, California + 27 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "National City",
          "state": "California"
        },
        {
          "city": "Paramount",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03959488"
    },
    {
      "nct_id": "NCT00001903",
      "title": "Prevention of RSV Infections in Bone Marrow Transplant Recipients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Infection"
      ],
      "interventions": [
        {
          "name": "RSV Polyclonal Immunoglobulin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 120,
      "start_date": "1999-04",
      "completion_date": "2001-05",
      "has_results": false,
      "last_update_posted_date": "2008-03-04",
      "last_synced_at": "2026-07-24T11:46:42.729Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001903"
    },
    {
      "nct_id": "NCT05083585",
      "title": "A Study Evaluating the Immunogenicity of Different Clinical Trial Materials of Ad26.RSV.preF- Based Vaccine in Adults Aged 60 - 75 Years Old",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Prevention"
      ],
      "interventions": [
        {
          "name": "Ad26.RSV.preF-based vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Janssen Vaccines & Prevention B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "60 Years to 75 Years"
      },
      "enrollment_count": 250,
      "start_date": "2021-10-08",
      "completion_date": "2022-09-22",
      "has_results": true,
      "last_update_posted_date": "2025-05-25",
      "last_synced_at": "2026-07-24T11:46:42.729Z",
      "location_count": 9,
      "location_summary": "San Diego, California • Lakeland, Florida • Melbourne, Florida + 4 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Lakeland",
          "state": "Florida"
        },
        {
          "city": "Melbourne",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05083585"
    },
    {
      "nct_id": "NCT02325791",
      "title": "Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Infections"
      ],
      "interventions": [
        {
          "name": "Suptavumab 30 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Placebo Matched to Suptavumab",
          "type": "DRUG"
        },
        {
          "name": "Suptavumab 30 mg/kg- 1 Dose",
          "type": "DRUG"
        },
        {
          "name": "Suptavumab 30 mg/kg - 2 Doses",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "6 Months",
        "sex": "ALL",
        "summary": "Up to 6 Months"
      },
      "enrollment_count": 1177,
      "start_date": "2015-07-21",
      "completion_date": "2017-09-26",
      "has_results": true,
      "last_update_posted_date": "2018-11-06",
      "last_synced_at": "2026-07-24T11:46:42.729Z",
      "location_count": 107,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 104 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Bell Gardens",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02325791"
    },
    {
      "nct_id": "NCT04908683",
      "title": "A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Respiratory Syncytial Viruses",
        "Lower Respiratory Tract Disease"
      ],
      "interventions": [
        {
          "name": "Adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV). preF",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Janssen Vaccines & Prevention B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 25236,
      "start_date": "2021-07-21",
      "completion_date": "2023-07-21",
      "has_results": true,
      "last_update_posted_date": "2025-11-13",
      "last_synced_at": "2026-07-24T11:46:42.729Z",
      "location_count": 156,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 126 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04908683"
    },
    {
      "nct_id": "NCT03473002",
      "title": "A Safety and Immunogenicity Study of Intranasal Sendai Virus Vectored Respiratory Syncytial Virus (SeVRSV) Vaccine in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Antiviral Prophylaxis",
        "Respiratory Syncytial Virus Infection"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "SeVRSV Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 21,
      "start_date": "2018-05-16",
      "completion_date": "2019-02-14",
      "has_results": false,
      "last_update_posted_date": "2019-03-01",
      "last_synced_at": "2026-07-24T11:46:42.729Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03473002"
    },
    {
      "nct_id": "NCT03982199",
      "title": "A Study of an Ad26.RSV.preF-based Regimen in the Prevention of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV)-Mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and Older",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Respiratory Syncytial Viruses",
        "Respiratory Tract Diseases"
      ],
      "interventions": [
        {
          "name": "RSV Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Janssen Vaccines & Prevention B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 5815,
      "start_date": "2019-08-01",
      "completion_date": "2023-05-26",
      "has_results": true,
      "last_update_posted_date": "2025-05-25",
      "last_synced_at": "2026-07-24T11:46:42.729Z",
      "location_count": 40,
      "location_summary": "Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 35 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03982199"
    },
    {
      "nct_id": "NCT06237296",
      "title": "Study of the Safety and Immune Response of an Investigational mRNA Vaccine for the Prevention of Respiratory Syncytial Virus and/or Human Metapneumovirus in Participants Aged 18 to 49 Years and 60 Years and Older",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Infection",
        "Healthy Volunteers",
        "Metapneumovirus Infection"
      ],
      "interventions": [
        {
          "name": "RSV/hMPV mRNA LNP 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSV/hMPV mRNA LNP 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSV mRNA LNP 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "hMPV mRNA LNP 1",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 558,
      "start_date": "2024-01-23",
      "completion_date": "2025-02-11",
      "has_results": false,
      "last_update_posted_date": "2025-09-11",
      "last_synced_at": "2026-07-24T11:46:42.729Z",
      "location_count": 9,
      "location_summary": "Gardena, California • Hallandale, Florida • Meridian, Idaho + 6 more",
      "locations": [
        {
          "city": "Gardena",
          "state": "California"
        },
        {
          "city": "Hallandale",
          "state": "Florida"
        },
        {
          "city": "Meridian",
          "state": "Idaho"
        },
        {
          "city": "Sioux City",
          "state": "Iowa"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06237296"
    }
  ]
}